Evolution of conjugate vaccines

References

• MacLeod CM, Hodges RG, Heidelberger M, Bernhard WG. Prevention of pneumococcal pneumonia by immunization with specific capsular polysaccharides. j Exp. Med. 82,445–465 (1945).
   Web of Science ®Google Scholar
• Austrian R, Douglas RM, Schiffman G et al Prevention of pneumococcal pneumonia by vaccination. Transact. Ass. Am. Phys. 89,184–194 (1976).
   PubMedGoogle Scholar
• Gold R, Artenstein M. Meningococcal infections 2. Field trial of group C meningococcal polysaccharide vaccine in 1969–70. BullWHO 45, 279–282 (1971).
   Google Scholar
• Wahdan MH, Rizt F, El-Akkad AM et al A controlled field trial of a serogroup A meningococcal polysaccharide vaccine. Bull. W'1048, 667–673 (1973).
   Google Scholar
• Peltola H, Kayhty H, Sivonen A, Makela PH. I-Lemophilus influenzaetype b capsular polysaccharide vaccine in children: A double-blind field study of 100,000 vaccinees 3 months to 5 years of age in Finland. Pediatrics 60,730–737 (1977).
   PubMed Web of Science ®Google Scholar
• •Demonstration of protective activity of a polysaccharide vaccine depending on age.
   Google Scholar
• Eskola J, Peltola H, Makela PH, Kayhty H, Karanko V, Samuelson J. Antibody levels achieved in infants by course of Hoemophilus influenz,ae type b polysaccharidekliphthteria toxoid conjugate vaccine. Lancet. i, 1184–1186 (1985).
   Google Scholar
• Timens W, Boes A, Rozeboom-Uiterwijk T, Poppema S. Immaturity of the human splenic marginal zone in infancy. Possible contribution to the deficient infant immune response. I Immunol 143,3200–3206 (1989).
   Google Scholar
• Barrett D, Sleasman J, Schatz D, Steinitz M. Human antipneumococcal polysaccharide antibodies are secreted by the CD5 B-cell lineage. Cell Immunol 143, 66–79 (1992).
   Google Scholar
• Eskola J, Peltola H, Takala AK et al kkemophilus influenz,ae type b polysaccharide-diphtheria toxoid conjugate vaccine is protective in infancy. N Engl. Med. 317,717–722 (1987).
   PubMed Web of Science ®Google Scholar
• •First demonstration of protection afforded by a conjugate vaccine.
   Google Scholar
• Black S, Shinefield H, Fireman B et al Efficacy, safety and immunogenicity of heptavalent pneumococcal conjugate vaccine in children. Northern California Kaiser Permanente Vaccine Study Center Group. Pecliatc Infect. Dis.j 19,187–195 (2000).
   PubMed Web of Science ®Google Scholar
• •First demonstration of protective ability of pneumococcal conjugate vaccine.
   Google Scholar
• Salisbury D. Introduction of a conjugate meningococcal type C vaccine programme in the UK. I Paecliatc Child Health 37, 534—S37 (2001).
   Google Scholar
• Kurikka S, Kayhty H, Saarinen L, Rönnberg P-R, Eskola J, Makela PH. Immunologic priming by one dose of kkemophilus influenzae type b conjugate vaccine in infancy. j Infect. Dis. 172, 1268–1272 (1995).
   Google Scholar
• Granoff DM, Anderson EL, Osterholm MT et al. Differences in the immunogenicity of three Haemophilus influenzae type b conjugate vaccines in infants. j Pediatr. 121, 187–194 (1992).
   PubMed Web of Science ®Google Scholar
• Goldblatt D, Vaz A, Miller E. Antibody avidity as a surrogate marker of successful priming by kkemophilus influenzae type b conjugate vaccines following infant immunization. Infect. Dis. 177,1112–1115 (1998).
   Google Scholar
• Takala AK, Eskola J, Leinonen M et al Reduction of oropharyngeal carriage of kkemophilus influenzae type b (Hib) in children immunized with a Hib conjugate vaccine. j Infect. Dis. 164,982–986 (1991).
   PubMed Web of Science ®Google Scholar
• ••Unexpected demonstration of a conjugatevaccine preventing carriage.
   Google Scholar
• Ward J, Brenneman G, Letson GW, Heyward WL. Limited efficacy of a 1–12 emophilus influenzae type b conjugate vaccine in Alaska Native infants. The Alaska H influenzae Vaccine Study Group. N Engl. I Med. 323, 1393–1401 (1990).
   Google Scholar
• Peltola H, Eskola J, Käyhty H, Takala AK, Makelä PH. Clinical comparison of the Haemophilus influenzae type b polysaccharide-diphtheria toxoid and the oligosaccharide-CRM197 protein vaccines in infancy. Arch. PecBab: Adolesc. Med 148, 620–625 (1994).
   Google Scholar
• Black SB, Shinefield HR, Fireman B et al. Efficacy in infancy of oligosaccharide conjugate Haemophilus influenzae type b (HbOC) vaccine in a United States population of 61 080 children. Pecliatr Infect. Dicj 10, 97–104 (1991).
   Google Scholar
• Barbour ML. Conjugate vaccines and the carriage of Haemophilus influenzae type b. Emerg. Infect. Dis. 2, 176–182 (1996).
   PubMed Web of Science ®Google Scholar
• Santosham M, Wolff M, Reid R et al The efficacy in Navajo infants of a conjugate vaccine consisting of Haemophilus intluenzaetype b polysaccharide and Neisseria meningitidis outer-membrane protein complex. N Engl. J. Med. 324, 1767–1772 (1991).
   PubMed Web of Science ®Google Scholar
• Booy R, Moxon ER, MacFarlane JA, Mayon-White RT, Slack MP. Efficacy of Haemophilus intluenzaetype b conjugate vaccines in Oxford region. Lancet 340, 847 (1992).
   Google Scholar
• Adegbola RA, Mulholland EK, Secka 0, Jaffar S, Greenwood BM. Vaccination with a Haemophilus influenzae type b conjugate vaccine reduces oropharyngeal carriage of H intluenzaetype b among Gambian children. Infect. Dis. 177, 1758–1761 (1998).
   Google Scholar
• Galil K, Singleton R, Levine OS et al Reemergence of invasive Haemophilus influenzae type b disease in a well-vaccinated population in remote Alaska. J. Infect. Dis. 179, 101–106 (1999).
   PubMed Web of Science ®Google Scholar
• •Unusual epidemiology affects effectiveness of conjugate vaccines.
   Google Scholar
• Kurikka S, Olander R-M, Eskola J, Käyhty H. Passively acquired antitetanus and antiHaemophilus antibodies and the response to Haemophilus influenzae type b - tetanus toxoid conjugate vaccine in infancy. Fed. Infect. Dis.j 15, 530–535 (1996).
   Google Scholar
• Nohynek H, Gustafsson L, Capeding MRZ etal. Effect of transpacentally aquired tetanus antibodies on the antibody responses to Haemophilus influenzae type b — tetanus toxoid conjugate and tetanus toxoid vaccines in Filipino infants. Pediatr. Infect. Dis. J. 18, 25–30 (1999).
   Google Scholar
• Capeding MR, Nohynek H, Pascual Let al The immunogenicity of three Haemophilus intluenzae type b conjugate vaccines after a primary vaccination series in Philippine infants. Am. J. Trop. Med. Hyg 55, 516–520 (1996).
   PubMed Web of Science ®Google Scholar
• Puumalainen T, Zeta-Capeding MR, Käyhty H et al Antibody response to an elevenvalent pneumococcal conjugate vaccine in Filipino infants. PediatE Infect. Dis. 21, 309–314 (2002).
   PubMedGoogle Scholar
• Robbins JB, Parke JC Jr, Schneerson R, Whistnant JK. Quantitative measurement of 'natural' and immunization induced .themophilus intluenzae type b capsular polysaccharide antibodies. Pecliatr Res. 7, 103–110 (1973).
   Google Scholar
• Phipps DC, West J, Eby R, Koster M, Madore DV, Quataert SA. An ELISA employing a Thernophilusinfluenzae type b oligosaccharide-human serum albumin conjugate correlates with the radioantigen binding assay. J. linmunol Meth. 135, 121–128 (1990).
   PubMed Web of Science ®Google Scholar
• Schreiber JR, Barrus V, Gates KL, Siber GR. Functional characterization of human IgG, IgM and IgA antibody directed to the capsule of .themophilus intluenzaetype b. J. Infect. Dis. 153, 8–16 (1986).
   PubMed Web of Science ®Google Scholar
• Käyhty H, Mäkelä 0, Eskola J, Saarinen L, Seppälä I. Isotype distribution and bactericidal activity of antibodies after immunization with Haemophilus influenzae type b vaccines at 18–24 months of age. J. Infect. Dis. 158, 973–982 (1988).
   Google Scholar
• Käyhty H, Peltola H, Karanko V, Mäkelä PH. The protective level of serum antibodies to the capsular polysaccharide of .themophilus intluenzaetype b. J. Infect. Dis. 147, 1100 (1983) and reply to the letter of Dr Porter Anderson, J. Infect. Dis. 149, 1034–1035 (1984).
   Google Scholar
• ••Estimation of antibody concentrationpredicting protection.
   Google Scholar
• Santosham M, Reid R, Ambrosino D et al Prevention of Themophilus intluenzaetype b infections in high-risk infants treated with bacterial polysaccharide immune globulin. N Engl. Med 317, 923–929 (1987).
   PubMed Web of Science ®Google Scholar
• •Different approach to determine concentration of antibody required for protection.
   Google Scholar
• Kurildca S. Priming with diphtheria- tetanus-pertussis vaccine enhances the response to the .themophilus intluenzaetype b tetanus conjugate vaccine in infancy. Vaccine 14, 1239–1242 (1996).
   Google Scholar
• Kurildca S, K.äyhty H, Peltola H, Eskola J, Saarinen L, Mäkelä PH. Neonatal immunization: response to Haemophilus influenzae type b - tetanus toxoid conjugate vaccine. Pediatrics 95, 815–822 (1995).
   Google Scholar
• Makeiä. 0, Mattila P, Rautonen N et al Isotype concentrations of human antibodies to Haemophilus influenzae type b polysaccharide (Hib) in young adults immunized with the polysaccharide as such or conjugated to a protein (diphtheria toxoid). Immund 139, 1999–2004 (1987).
   Google Scholar
• Schlesinger Y, Granoff DM, the Vaccine Study Group. Avidity and bacterial activity of antibody elicited by different .themophilus intluenzae type b conjugate vaccines. JAIVIA 267(11), 1489 (1992).
   Google Scholar
• Ward JI, Lum MK, Hall DB, Silimperi DR, Bender TR. Invasive Haemophilus influenzae type b disease in Alaska: background epidemiology for a vaccine efficacy trial. Infect. Dis. 153, 17–26 (1986).
   Google Scholar
• Peltola H. Worldwide Haemophilus influenzae type b disease at the beginning of the 21st century: Global analysis of the disease burden 25 years after the use of the polysaccharide vaccine and a decade after the advent of conjugates. GYM Microbial. Rev 13(2), 302–317 (2000).
   Google Scholar
• •Worldwide introduction of Hib vaccine.
   Google Scholar
• Mulholland K, Hilton S, Adegbola R et al. Randomised trial of Haemophilus influenzae type-b tetanus protein conjugate vaccine [corrected] for prevention of pneumonia and meningitis in Gambian infants. Lancet 349 (9060), 1191–1197 (1997).
   PubMed Web of Science ®Google Scholar
• ••Hib vaccine as a probe to demonstrateHib bacteria as an important and preventable cause of pneumonia.
   Google Scholar
• Peltola H. Spectrum and burden of severe Haemophilus influenzae type b diseases in Asia. Bull. WH077(11), 878–887 (1999).
   Google Scholar
• Kauppi M, Saarinen L, Käyhty H. Anticapsular polysaccharide antibodies reduce nasopharyngeal colonization by Haemophilus influenzae type b in infant rats. Infect. Dis. 167, 365–371 (1993).
   Google Scholar
• Kauppi M, Eskola J, Käyhty H. Anticapsular polysaccharide antibody concentrations in saliva after immunization with Haemophilus influenzae type b conjugate vaccines. PediatE Infect. Dis. 14, 286–294 (1995).
   Google Scholar
• Eskola J, Käyhty H. Ten years' experience with Haemophilus intluenzae type b (Hib) conjugate vaccines in Finland. Rev Merl Microbial. (4), 231–241 (1996).
   Google Scholar
• Moulton L, Chung S, Kroll J, Reid R, Weatherholtz R, Santosham M. Estimation of the indirect effect of Haemophilus intluenzae type b conjugate vaccine in an American Indian population. Int. Epidemiol 29, 753–756 (2000).
   PubMed Web of Science ®Google Scholar
• Takala AK, Santosham M, Almeido-Hill J et al Vaccination with Haemophilus intluenzae type b meningococcal protein conjugate vaccine reduces oropharyngeal carriage of Haemophilus intluenzae type b among American indian children. PediatE Infect. Dicj 12, 593–599 (1993).
   PubMed Web of Science ®Google Scholar
• Mäkelä PH, Käyhty H, Leino T et al Long-term persistence of immunity after conjugate vaccines, analysed with Hib vaccine as a model. Vaccine In press (2002).
   Google Scholar
• Leino T, Auranen K, Mäkelä PH et al Haemophilus intluenzae type b and cross-reactive antigens in natural Hib infection dynamics; modelling in two populations. Epidemiol Infect. 129, 73–83 (2002).
   Google Scholar
• Bradshaw M, Schneerson R, Parke J, Robbins J. Bacterial antigens cross-reactive with the capsular polysaccharide of Haemophilus intluenzae type b. Lancet i, 1095–1097 (1971).
   Google Scholar
• Mbelle N, Huebner R, Wasas A, Kimura A, Chang I, Klugman K. Immunogenicity and impact on nasopharyngeal carriage of a nonavalent pneumococcal conjugate vaccine. Infect. Dis. 180, 1171–1176 (1999).
   Google Scholar
• Quataert S, Martin D, Anderson P et al A multi-laboratory evaluation of an enzyme-linked immunoassay quantitating human antibodies to Streptococcus pneumoniae polysaccharides. Immunol Invest. 30(3), 191–207 (2001).
   Google Scholar
• Soininen A, van den Dobbelsteen G, Oomen L, Kayhty H. Are the enzyme immunoassays for antibodies to pneumococcal capsular polysaccharides serotype specific? Gun. Diagn. Lab. Immunol 7, 468–476 (2000).
   PubMedGoogle Scholar
• Concepcion NF, Frasch CE. Pneumococcal type 22f polysaccharide absorption improves the specificity of a pneumococcal-polysaccharide enzyme-linked immunosorbent assay. Gun. Diagn. Lab. Immunol 8, 266–272 (2001).
   Google Scholar
• Romero-Steiner S, Libutti D, Pais LB et al. Standardization of an opsonophagocytic assay for the measurement of functional antibody activity against Streptococcus pneumoniae using differentiated HL-60 cells. Gun. Diagn. Lab. Immunol 4, 415–422 (1997).
   Google Scholar
• Väkevainen M, Jansen W, Saeland E et al. Are the opsonophagocytic activities of antibodies in infant sera measured by different pneumococcal phagocytosis assays comparable? Gun. Diagn. Lab. Immunol 8, 363–369 (2001).
   PubMedGoogle Scholar
• Ahman H, Käyhty H, Lehtonen H, Leroy 0, Froeschle J, Eskola J. Streptococcus pneumoniae capsular polysaccharide-diphtheria toxoid conjugate vaccine is immunogenic in early infancy and able to induce immunologic memory. PerliatE Infect. Dis.j 17, 211–216 (1998).
   Google Scholar
• Wuorimaa T, Dagan R, Väkeväinen M et al. Avidity and subclasses of IgG after immunization of infants with an 11-valent pneumococcal conjugate vaccine with and without aluminum adjuvant. J. Infect. Dis. 184,1211-1215(2001).
   Google Scholar
• Anttila M, Voutilainen M, Jäntti V, Eskola J, Käyhty H. Contribution of serotype-specific IgG concentration, IgG subclasses and relative antibody avidity to opsonophagocytic activity against Streptococcus pneumoniae. Clin. Exp. Immunol 118, 402–407 (1999).
   Google Scholar
• Anttila M, Eskola J, Ahman H, Käyhty H. Differences in the avidity of antibodies evoked by four different pneumococcal conjugate vaccines in early childhood. Vaccine 17, 1970–1977 (1999).
   Google Scholar
• Usinger WR, Lucas AH. Avidity as a determinant of the protective efficacy of human antibodies to pneumococcal capsular polysaccharides. Infect. IMMUIL 67(5), 2366–2370 (1999).
   PubMed Web of Science ®Google Scholar
• Whitney CG, Lynfield R, Hadler J et al Conjugate vaccine impact on antimicrobial resistance in pneumococci in the USA Abstracts of ISPPD-2002, the 3rd International Symposium on Pneumococci and Pneumococcal Diseases. Anchorage, Alaska, USA, 108 (2002).
   Google Scholar
• Eskola J, Kilpi T, Palmu A et al. Efficacy of a pneumococcal conjugate vaccine against acute otitis media. N Engl. I Med. 344, 403–409 (2001).
   PubMed Web of Science ®Google Scholar
• •Pneumococcal vaccine less effective in protection from otitis media.
   Google Scholar
• Kilpi T, Palmu A, Leinonen M, Eskola J, Finom SG. Efficacy of a 7-valentpneumococcal conjugate vaccine (PncOMPC) against serotype-specific AOM caused by pneumococci. 40th Interscience Conference on Antimicrobial Agents and Chemotherapy (ICAAC), American Society for Microbiology, Toronto, Canada, poster 689, 245 (2000).
   Google Scholar
• Black S, Shinefield H, Ray P et al Efficacy of a heptavalent pneumococcal conjugate vaccine (Wyeth Lederle) in 37,000 infants and children: impact on pneumonia, otitis media and an update on invasive disease. Results extended follow-up of the efficacy trial cohort of the abstracts of ISPPD-2000, the 2nd International Symposium on Pneumococci and Pneumococcal Diseases. Sun City, SA (2000).
   Google Scholar
• O'Brien KL, David A, Benson J et al The effect of conjugate pneumococcal vaccine on pneumonia and otitis media among Navajo and White Mountain Apache children. Presentation at ISPPD-2002, the 3rd International Symposium on Pneumococci and Pneumococcal Diseases. Anchorage, Alaska, USA, 110 (2002).
   Google Scholar
• Klugman K. Presentation at ISPPD-2002, the 3rd International Symposium on Pneumococci and Pneumococcal Diseases. Anchorage, Alaska, USA (2002).
   Google Scholar
• Dagan R, Melamed R, Muallem M et al Reduction of nasopharyngeal carriage of pneumococci during the second year of life by a heptavalent conjugate pneumococcal vaccine. Infect. as 174, 1271–1278 (1996).
   PubMed Web of Science ®Google Scholar
• Obaro S, Adegbola R, Banya W, Greenwood B. Carriage of pneumococciafter pneumococcal vaccination. Lancet 348, 271–272 (1996).
   PubMed Web of Science ®Google Scholar
• Millar EV, O'Brien KL, Watt JP etal. Duration of protection against pneumococcal nasopharyngeal carriage by 7-valent pneumococcal conjugate vaccine (PnCRM7) in Navajo and Apache children. Abstracts of ISPPD-2002, the 3rd International Symposium on Pneumococci and Pneumococcal Diseases. Anchorage, Alaska, USA, 54 (2002).
   Google Scholar
• Palmu AA, Kaijalainen T, Verho J, Herva E, Mäkelä PH, Kilpi TM. Long-term efficacy of the sevenvalent PncCRM vaccine on nasopharyngeal carriage. Abstracts of ISPPD-2002, the 3rd International Symposium on Pneumococci and Pneumococcal Diseases. Anchorage, Alaska, USA, 24 (2002).
   Google Scholar
• Sprott B, Greenwood B. Prevention of pneumococcal disease by vaccination: does serotype replacement matter? Lancet 356, 1210–1211 (2000).
   Google Scholar
• Peltola H, Makela PH, Kayhty H et al Clinical efficacy of meningococcus group A capsular polysaccharide vaccine in children three months to five years of age. N Engl. Med 297,686–691 (1977).
   PubMed Web of Science ®Google Scholar
• Finne J, Leinonen M, Makela PH. Antigenic similarities between brain components and bacteria causing meningitis. Lancet ii, 355–357 (1983).
   Google Scholar
• Griffis JM, Yamasaki R, Estabrook M, Kim JJ. Meningococcal molecular mimicry and the search for an ideal vaccine. Trans. I?. Soc. Top. Med Hyg 85\(Suppl. 1), S32-36 (1991).
   Google Scholar
• MacDonald NE, Halperin S, Law B, Forrest BD, Danzig LE, Granoff DM. Induction of immunologic memory by conjugated vs plain meningococcal C polysaccharide vaccine in toddlers: a randomized controlled trial. JAIVIA 280, 1685–1689 (1998).
   PubMed Web of Science ®Google Scholar
• Fairley CK, Begg N, Borrow R, Fox AJ, Jones DM, Cartwright K. Conjugate meningococcal serogroup A and C vaccine: reactogenicity and immunogenicity in United Kingdom infants. J. Infect. Dir. 174, 1360–1363 (1996).
   PubMed Web of Science ®Google Scholar
• Leach A, Twumasi PA, Kumah S etal. Induction of immunologic memory in Gambian children by vaccination in infancy with a group A plus group C meningococcal polysaccharide-protein conjugate vaccine. J. Infect. Dis. 175,200–204 (1997).
   Google Scholar
• •Good imrnunogenicity of meningococcal conjugates.
   Google Scholar
• MacLennan JM, Shockley F, Heath PT et al. Safety, immunogenicity and induction of immunologic memory by a serogroup C meningococcal conjugate vaccine in infants: a randomized controlled trial. 161/1//A 283,2795–2801 (2000).
   Google Scholar
• MacLennan J, Obaro S, Deeks J et al Immunologic memory 5 years after meningococcal A/C conjugate vaccination in infancy. Infect. Dis. 183,97-104 (2001).
   Google Scholar
• Richmond P, Borrow R, Goldblatt DE et al. Ability of 3 different meningococcal C conjugate vaccines to induce immunologic memory after a single dose in UK toddlers. .1. Infect. Dis. 183,160-163 (2001).
   Google Scholar
• Artenstein MS, Brandt BL. Immunologic hyporesponsiveness in man to group C meningococcal polysaccharide. J. Immunol 115,5–7 (1975).
   PubMed Web of Science ®Google Scholar
• Gold R, Lepow ML, Goldschneider I, Gotschlich EC. Immune response of human infants to polysaccharide vaccines of group A and C Neisseria meningitidis. Infect. Dis. 136(Suppl.), S31-35 (1977).
   Google Scholar
• Goldschneider I, Gotschlich EC, Artenstein MS. Human immunity to the meningococcus-II. Development of natural immunity. Exp. Med 129,1327–1348 (1969).
   Google Scholar
• Ramsay ME, Andrews N, Kaczmarski EB, Miller E. Efficacy of meningococcal serogroup C conjugate vaccine in teenagers and toddlers in England. Lancet 357,195–196 (2001).
   PubMed Web of Science ®Google Scholar
• •First demonstration of protective effect of a meningococcal conjugate vaccine.
   Google Scholar
• Lipsitch M. Bacterial vaccines and serotype replacement: lessons from Haemophilus influenzae and prospects for Streptococcus pneumoniae. Emerg Infect. Dis. 5(3), 336–345 (1999).
   Google Scholar
• Briles DE, Hollingshead S, Brooks-Walter A et al The potential to use PspA and other pneumococcal proteins to elicit protection against pneumococcal infection. Vaccine 18(16), 1707–1711 (2000).
   PubMed Web of Science ®Google Scholar
• Jokinen J, Ahman H, Kilpi T et al The concentration of antipneumococcal antibodies as a serological correlate of protection — a case study of acute otitis media. Abstracts of ISPPD-2002, the 3rd International Symposium on Pneumococci and Pneumococcal Diseases. Anchorage, Alaska, USA, 68 (2002).
   Google Scholar
• Dagan R, Botujansky C, Watemberg N et al Safety and immunogenicity in young infants of Haemophilusb-tetanus protein conjugate vaccine, mixed in the same syringe with diphtheria-tetanus-pertussis-enhanced inactivated poliovirus vaccine. Perliatc Infect. Dis.j 13,356–361 (1994).
   PubMed Web of Science ®Google Scholar
• Mulholland EK, Ahonkhai VI, Greenwood AM et al Safety and immonogenicity of Haernophilus influenzaetypeB-Neisseria meningitidisgroup B outer membrane protein complex conjugate vaccine mixed in the syringe with diphtheria-tetanus-pertussis vaccine in young Gambian infants. Pediatc Infect. DIS.J 12,632–637 (1993).
   PubMed Web of Science ®Google Scholar
• Eskola J, ölander R-M, Hovi T, Litmanen L, Peltola S, Kayhty H. Randomized trial of the effect of co-administration with acellular pertussis DTP vaccine on immunogenicity of Haemophilus influenzae type b conjugate vaccine. Lancet 348, 1688–1692 (1996).
   Google Scholar
• Garpenholt 0, Hugosson S, Fredlund H, Giesecke J, Oken P. Invasive disease due to Haemophilus influenzae type b during the first six years of general vaccination of Swedish children. Acta Paediatc 89(4), 471–474 (2000).
   Google Scholar
• Schmitt HJ, von Kries R, Hassenpflug B et al Haemophilus influenzaetype b disease: impact and effectiveness of diphtheria-tetanus toxoids-acellular pertussis (-inactivated poliovirus)/H. influenzae type b combination vaccines. Pecliah: Infect. Dis. 20(8), 767–774 (2001).
   Google Scholar
• Sankilampi U, Honkanen PO, Bloigu A, Herva E, Leinonen M. Antibody response to pneumococcal capsular polysaccharide vaccine in the elderly. I Infect. Dis. 173, 387–393 (1996).
   Google Scholar
• Schneider L, Insel R, Howie G, Madore D, Geha R. Response to a Haemophilus influenzae type b diphtheria CRM197 conjugate vaccine in children with a defect of antibody production to Haemophilus influenzae type b polysaccharide. I Allergy Clin. Immunol 85,948–953 (1990).
   Google Scholar
• Powers DC, Anderson EL, Lottenbach K, Mink CM. Reactogenicity and immunogenicity of a protein-conjugated pneumococcal oligosaccharide vaccine in older adults. Infect. Dis. 173,1014–1018 (1996).
   Google Scholar
• GAVI, Global Alliance for Vaccines and Immunizations. www.vaccinealliance.org.
   Google Scholar